
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics Inc. is positioned favorably in the clinical-stage precision medicine sector due to its innovative Dynamo platform, which effectively addresses challenging drug-protein targets and is set to enhance the development of promising oncology and genetic disease treatments. The company’s product candidate, RLY-2608, is anticipated to gain significant market share as its clinical data suggests superior efficacy and a better tolerability profile compared to existing treatments such as capivasertib, indicating it may facilitate longer duration therapies and broader market expansions. This potential for rapid market adoption, in conjunction with the successful performance of capivasertib in exceeding sales expectations and expanding its market to approximately $700 million, underscores a highly optimistic outlook for Relay Therapeutics’s stock.
Bears say
Relay Therapeutics Inc. is experiencing a significant decline in expected median progression-free survival (mPFS) from 24 months to just 5 months, which may adversely affect patient outcomes and market acceptance of its therapies. Furthermore, safety concerns associated with inavolisib have negatively impacted its commercial launch, yielding disappointing results that fall short of expectations for a first-line product. The company is also facing increased competition in its market, exemplified by the reported decline in sales for Piqray, highlighting broader challenges within its commercial landscape.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares